EUCTR2011-006288-23-FR进行中（未招募）1 期
Randomized double blind placebo-controlled phase II trial of Vargatef® in addition to first line chemotherapy with interval debulking surgery in patients with adenocarcinoma of the ovary, the fallopian tube or serous adenocarcinoma of the peritoneum - CHIVA
ARCAGY0 个研究点目标入组 188 人开始时间: 2012年9月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 188
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •First diagnosis of histological confirmed (cytology alone excluded) epithelial ovarian cancer, fallopian tube or primary peritoneal cancer. Histology should be obtained by laparoscopy (or by laparotomy),
- •FIGO-Stages IIIC – IV,
- •Females, age 18 years or older,
- •Life expectancy of at least 6 months,
- •ECOG performance status < 2,
- •Primary debulking surgery denied and maximum surgical effort of cytoreduction with the goal of no residual disease planned as interval debulking surgery,
- •Patient has given written informed consent,
- •Interval between diagnosis and enrolment (informed consent) = 8 weeks,
- •Adequate hepatic, renal and bone marrow functions.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 188
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Histological diagnosis of malignant tumour of non-epithelial origin (e.g. germ cell tumour, malignant mixed mullerian tumour, sex cord-stromal tumour) of the ovary, the fallopian tube or peritoneum or borderline tumour of the ovary (tumour of low malignant potential),
- •Non-healing wound, ulcer (intestinal tract, skin) or bone fracture,
- •Clinical symptoms or signs of gastrointestinal obstruction that require parenteral nutrition and/or hydration,
- •History of major thromboembolic event,
- •History of at least 2 unprovoked (without a transient or reversible risk factor) events of proximal deep venous thrombosis,
- •Prior thrombosis or thromboembolic event in the presence of an inherited coagulopathy (including deficiency of antithrombin, deficiency of protein C or protein S, Factor V Leiden mutation, Prothrombin G20210A mutation),
- •Patients with perioperative thrombosis including proximal deep vein thrombosis (DVT) or thrombosis of visceral vessels not associated with pulmonary embolism may be included in the trial if stable therapeutic anticoagulation is documented,
- •Known inherited or acquired bleeding disorder,
- •Significant cardiovascular diseases,
- •Peripheral vascular disease Fontaine stage =3,
- •Clinically relevant pericardial effusion (e.g. pericardial effusion with echocardiographic or clinical signs of haemodynamic impairment),
- •History of a cerebral vascular accident, transient ischemic attack or subarachnoid hemorrhage within the past 6 months,
- •Serious infections in particular if requiring systemic antibiotic (antimicrobial,
- •antifungal) or antiviral therapy,
- •Poorly controlled diabetes mellitus or other contraindication to high dose corticosteroid therapy,
- •Clinical symptoms of brain metastases and/or diagnosis of brain metastases on imaging,
- •Pre-existing sensory or motor neuropathy CTCAE = 2, except due to trauma,
- •Gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug,
- •Other malignancy diagnosed within the past 5 years,
- •Prior systemic therapy for ovarian cancer (e.g. chemotherapy, monoclonal antibody therapy, oral targeted therapy, hormonal therapy),
- •Prior radiotherapy to the abdomen or prior radiotherapy to an extra-abdominal target volume that would bear the risk of increased toxicity of chemotherapy,
- •Hypersensitivity to BIBF 1120 and/or the excipients of the trial drugs,
- •Serious illness or concomitant non-oncological disease such as neurologic, psychiatric or infectious disease, active ulcers (gastrointestinal tract, skin) or a laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study,
- •Patients with preserved reproductive capacity who are sexually active and unwilling to use a medically acceptable method of contraception (e.g. such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner) during the trial and for at least twelve months after end of active therapy,
- •Pregnancy or breast feeding,
- •Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule,
- •Active alcohol or drug abuse,
- •Any contraindications for therapy with paclitaxel or carboplatin, e.g. a history of severe hypersensitivity reactions to paclitaxel or platinum-conta
研究者
相似试验
招募中
2 期
Randomized double blind placebo-controlled phase II study on the effects of EA-230 on the innate immune response following on-pump cardiac surgeryimmune systemInflammatory repsonse1002766510038430NL-OMON42527Exponential Biotherapies Inc.160
进行中（未招募）
1 期
Study on the effects of EA-230 on the immune system following heart surgeryEUCTR2015-005600-28-NLExponential Biotherapies Inc.160
进行中（未招募）
不适用
Randomized double-blind placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent, persistent and/or metastasizing) medullary thyroid carcinoma (SUMMIT).EUCTR2011-006250-90-ATEANM Forschungs GmbH / EANM Research Ltd.110
进行中（未招募）
不适用
Randomized double-blind placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent, persistent and/or metastasizing) medullary thyroid carcinoma (SUMMIT).Advanced (recurrent, persistent and/or metastasizing) medullary thyroid carcinomaEUCTR2011-006250-90-DEEANM Forschungs GmbH / EANM Research Ltd.110
进行中（未招募）
3 期
Assessing the effect of Triumeq in amyotrophic lateral sclerosisAmyotrophic Lateral Sclerosis (ALS)Nervous System DiseasesMotor neuron diseaseISRCTN88446415King's College London390